首页> 外文期刊>Endocrine journal >Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients
【24h】

Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients

机译:甲状腺球蛋白抗体阳性的甲状腺乳头状癌患者全甲状腺切除术前后血清甲状腺球蛋白抗体水平变化的预后意义

获取原文
获取原文并翻译 | 示例
           

摘要

Although postoperative serum thyroglobulin (Tg) is a prognostic indicator for papillary thyroid carcinoma (PTC), it is unreliable when Tg antibody (TgAb) is positive. We evaluated the prognostic significance of changes in serum TgAb levels of pre- and post-total thyroidectomy in TgAb-positive PTC patients. We reviewed our medical charts of 225 TgAb-positive PTC patients in whom TgAb levels were measured before and 1-2 years after total thyroidectomy, performed between April 2002 and March 2007. We divided them into 3 groups based on changes in TgAb levels. Postoperative serum TgAb levels decreased by >50% in 181 patients (80.4%) (Group 1), by <50% in 22 patients (9.8%) (Group 2), and increased in 22 patients (9.8%) (Group 3). During the follow-up, 3 patients died of the disease and 14 patients had recurrences. All 3 patients who died of PTC were seen only in Groups 2 and 3. Groups 2 and 3 showed similar prognostic outcomes, thus were analyzed together as Group 2+3. Group 1 had significantly better lymph node recurrence-free survival and distant recurrence-free survival than Group 2+3 (96.9% vs. 90.5%, p <0.001, and 98.9% vs. 90.1%, p = 0.004, respectively at 5 years). Multivariate analyses on prognostic factors revealed that classification to Group 2+3 was the strongest indicator for poor prognosis. The present results suggest that changes in TgAb levels following total thyroidectomy can be an important dynamic prognostic factor of PTC patients. Prospective periodical measurements of TgAb are necessary to confirm these findings.
机译:尽管术后血清甲状腺球蛋白(Tg)是甲状腺乳头状癌(PTC)的预后指标,但当Tg抗体(TgAb)呈阳性时,它是不可靠的。我们评估了TgAb阳性PTC患者甲状腺切除术前后总血清TgAb水平改变的预后意义。我们回顾了我们2002年4月至2007年3月进行的225例TgAb阳性PTC患者的医学图表,这些患者在进行全甲状腺切除术之前和之后1-2年测量了TgAb的水平。根据TgAb的变化将他们分为3组。 181名患者(80.4%)(组1)术后血清TgAb水平下降> 50%,22名患者(9.8%)(组2)下降<50%,22名患者(9.8%)(3组)上升。在随访期间,3例患者死于该病,14例患者复发。仅在第2组和第3组中发现了所有3例因PTC死亡的患者。第2组和第3组显示了相似的预后结果,因此一起作为第2 + 3组进行分析。与第2 + 3组相比,第1组的淋巴结无复发生存率和远处无复发生存率明显好于第5组(分别为96.9%比90.5%,p <0.001,以及98.9%比90.1%,p = 0.004,p = 0.004) )。对预后因素的多变量分析显示,分类为2 + 3组是预后不良的最强指标。目前的结果表明,全甲状腺切除术后TgAb水平的变化可能是PTC患者重要的动态预后因素。 TgAb的前瞻性定期测量对于确认这些发现是必要的。

著录项

  • 来源
    《Endocrine journal》 |2013年第7期|871-876|共6页
  • 作者单位

    Department of Breast and Endocrine Surgery, Nagoya University, Nagoya 466-8550, Japan,Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan,Department of Breast and Endocrine Surgery, Nagoya University, 65 Tsurumai-cho, Syowa-ku, Nagoya 466-8550, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Internal Medicine, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan;

    Department of Breast and Endocrine Surgery, Nagoya University, Nagoya 466-8550, Japan;

    Department of Breast and Endocrine Surgery, Nagoya University, Nagoya 466-8550, Japan;

    Department of Transplantation, Nagoya University, Nagoya 466-8550, Japan;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Thyroglobulin antibody; Papillary thyroid carcinoma; Prognostic factor;

    机译:甲状腺球蛋白抗体;甲状腺乳头状癌预后因素;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号